An International Journal of Otorhinolaryngology Clinics

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 15 , ISSUE 3 ( September-December, 2023 ) > List of Articles

Original Article

Study of HRCT Score, Comorbidities, Specific Blood Findings, and Management of COVID-positive Patients at Dr DY Patil Medical College and Hospital, Pune

Rashmi P Rajashekhar, Ruchir Dashora, Gundappa D Mahajan, Anis Narayan Sur

Keywords : COVID-19, COVID-19 pneumonia, COVID-19 study, HRCT thorax score

Citation Information : Rajashekhar RP, Dashora R, Mahajan GD, Sur AN. Study of HRCT Score, Comorbidities, Specific Blood Findings, and Management of COVID-positive Patients at Dr DY Patil Medical College and Hospital, Pune. Int J Otorhinolaryngol Clin 2023; 15 (3):99-102.

DOI: 10.5005/jp-journals-10003-1452

License: CC BY-NC 4.0

Published Online: 09-01-2024

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Aim: Study of HRCT score, comorbidities, specific blood findings, and management of COVID-positive patients at Dr DY Patil Medical College and Hospital, Pune. Materials and methods: We conducted a prospective study of all hospitalized cases of COVID infection in Dr DY Patil Medical College and Hospital, admitted between April and May 2021 from COVID ward 405. The study was conducted in respect to the severity of symptoms, comorbidities, HRCT chest score, the specific blood parameters, requirement of oxygen, and different treatment modalities. The inclusion criterion was admitted patients diagnosed with COVID-19. We excluded those with suspected COVID-19 infection but with negative RT-PCR reports. Also, we excluded patients diagnosed with COVID-19 who were advised home quarantine. COVID-19 infection was confirmed by RT-PCR using swab samples from the nasopharynx and oropharynx. Tests were carried out with the COVID-19 RT-PCR. Results: In our study, on CO-RADS score, we found 42% were mild, 32% were moderate, and 26% were severe. We found that out of 50 patients, only 1 received a complete dose of Covishield vaccine and only 4 received the 1st dose of Covishield vaccine. We found that out of 50 patients, only 40 patients required oxygen therapy. Patients who were on high CO-RADS scores, received a dose of remdesivir + clexane + dexamethasone. We found that out of 50 patients, 4 patients were suffering from asthma. We found that out of 50 patients, 15 patients were suffering from diabetes mellitus type 2. We found that out of 50 patients, 1 patient was suffering from chronic renal disease. Conclusion: In this prospective study done at Dr DY Patil Medical College in COVID-positive ward (sample size of 50), we came to find out the most common HRCT thorax score is between 1 and 7 (mild). Out of 50 patients, 15 were suffering from type 2 diabetes mellitus. And out of these, 13 patients were >50 years of age. In this study, out of 50 patients, those who received remdesivir + dexamethasone + clexane were 6 patients. In this study, out of 50 patients with diabetes mellitus and age above 50 years were 13 patients. Only 1 patient received 2 doses of the COVID vaccine (Covishield). One patient was suffering from chronic renal disease and needed dialysis.

HTML PDF Share
  1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92(4):418–423. DOI: 10.1002/jmv.25681.
  2. Seah I, Agrawal R. Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm 2020;28(3):391–395. DOI: 10.1080/09273948.2020.1738501.
  3. Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls 2021. PMID: 32150360.
  4. De Haan CA, Kuo L, Masters PS, et al. Coronavirus particle assembly: Primary structure requirements of the membrane protein. J Virol 1998;72(8):6838–6850. DOI: 10.1128/JVI.72.8.6838-6850.1998.
  5. Woo PCY, Huang Y, Lau SKP, et al. Coronavirus genomics and bioinformatics analysis. Viruses 2010;2(8):1804–1820. DOI: 10.3390/v2081803.
  6. Czub M, Weingartl H, Czub S, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 2005;23(17–18):2273–2279. DOI: 10.1016/j.vaccine.2005.01.033.
  7. Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3’ and 5’ ends. Virus Res 2015;206:120–133. DOI: 10.1016/j.virusres.2015.02.025.
  8. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. The Lancet 2020;395(10224):565–574. DOI: 10.1016/S0140-6736(20)30251-8.
  9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–280.e8. DOI: 10.1016/j.cell.2020.02.052.
  10. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – An update on the status. Mil Med Res 2020;7(1):11. DOI: 10.1186/s40779-020-00240-0.
  11. Sola I, Almazan F, Zuniga S, et al. Continuous and discontinuous RNA synthesis in coronaviruses. Annual review of virology 2015 9;2:265–288. DOI: 10.1146/annurev-virology-100114-055218.
  12. Ziebuhr J. The coronavirus replicase. Curr Top Microbiol Immunol 2005;287:57–94. DOI: 10.1007/3-540-26765-4_3.
  13. Almazán F, DeDiego ML, Galán C, et al. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol 2006;80(21):10900–10906. DOI: 10.1128/JVI.00385-06.
  14. McIntosh K, Peiris JS. Coronaviruses. In: Clinical Virology, 3rd ed. American Society of Microbiology 2009. pp. 1155–1171.
  15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
  16. Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6(3):315–331. DOI: 10.1021/acscentsci.0c00272.
  17. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV – A target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3):226–236. DOI: 10.1038/nrmicro2090.
  18. Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004;314(1):235–241. DOI: 10.1016/j.bbrc.2003.12.081.
  19. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020;81(5):537–540. DOI: 10.1002/ddr.21656.
  20. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9(396):eaal3653. DOI: 10.1126/scitranslmed.aal3653.
  21. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020;64(5):e00399–20. DOI: 10.1128/AAC.00399-20.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.